<DOC>
	<DOCNO>NCT02400164</DOCNO>
	<brief_summary>The study multi-center , prospective , open label , uncontrolled feasibility study enrol 30 patient refractory recurrent ascites cirrhosis 6 site . Patients enrol 6 month enrollment phase data collect 12months initial analysis 3 month . Extended follow-up safety monitoring purpose continue lifetime patient device explanted .</brief_summary>
	<brief_title>A ( M ) Ulti-center , Prospective , ( O ) Pen Label , Uncontrolled Feasibility ( S ) Tudy Assess Safety Effectiveness Automatic Low Flow ( A ) Scites ( Alfa ) Pump ( I ) n Patients With ( C ) Irrhosis Refractory Recurrent Ascites</brief_title>
	<detailed_description />
	<mesh_term>Ascites</mesh_term>
	<criteria>1. patient ≥ 21 year age 2. recurrence grade 3 ascites require paracentesis symptom relief frequently per month minimum 2 prior 3 month 3. cirrhosis etiology 4. failure respond intolerance high dose diuretic 5. expect survival great 3 month ( MELD score ≤ 21 ) 6. screen varix optimal management 7. diagnostic paracentesis neutrophil count &lt; 250 / µl within 24 hour implantation 8. write informed consent 9. ability comply study procedure ability operate device 10. woman childbearing potential use adequate contraception 1. 2 systemic local infection , peritonitis , urinary tract infection , abdominal skin infection within last 6 month 2. presence current cancer 3. evidence extensive ascites loculation 4. serum creatinine &gt; 1.5 mg/dl 5. serum bilirubin &gt; 5 mg/dl 6. eGFR &lt; 30 ml/min/1.73m2 MDRD ( Modification Diet Renal Disease ) method 7. gastrointestinal hemorrhage due portal hypertension 2 week prior inclusion study 8. hepatic encephalopathy &gt; stage II two week prior implant 9. presence patent TIPS surgical portosystemic shunt 10. presence BuddChiari syndrome 11. previous solid organ transplant 12. obstructive uropathy ( bladder residual volume &gt; 100ml ( determine catheterization abdominal ultrasound ) bladder anomaly may contraindicate implantation alfapump , include recurrent urinary tract infection , vesicoureteral reflux , history urinary calculus ) 13. International Prostate Symptom Score ( IPSS ) ≥20 14. thrombocytopenia &lt; 45,000 X106/l 15. patient undergo therapeutic anticoagulation 16. recent ( &lt; 4 month ) intraabdominal foreign body abdominal surgery , diaphragmatic hernia , abdominal surgery , severe abdominal adhesion , surgically irreparable hernia , abdominal wall skin infection , severe malnutrition . 17. history ( &gt; 6 month ) diaphragmatic hernia , history bladder cancer , inflammatory ischemic bowel disease , frequent episode diverticulitis . 18. nonliver disease life expectancy &lt; 1 year 19. patient eligible TIPS ( unless refuse TIPS placement ) . 20. presence active implantable bodyworn device remove 21. pregnancy 22. patient another therapeutic clinical study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>